PITTSBURGH , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a presenting company at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference . The

Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21 Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis expected in 3Q21 Our wholly-owned subsidiary Jeune Aesthetics, Inc.

KB301 is designed to deliver a full-length human type III collagen transgene via intradermal injection Initial data from this efficacy cohort of the PEARL-1 study is anticipated in 4Q21 PITTSBURGH, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc., a wholly-owned subsidiary of Krystal

-  New data include update from the fourth patient treated in the Phase 1/2 trial -  Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response PITTSBURGH , July 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two upcoming virtual investor conferences. Details for the events are as follows: Goldman Sachs 42nd Annual

Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4 million PITTSBURGH , May 10, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc.

PITTSBURGH , May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth has more than 25 years of global biotechnology experience,

PITTSBURGH , April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present preclinical data from its vector-encoded-antibody platform in a digital poster presentation at the

PITTSBURGH , April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the Statistical Analysis Plan (SAP) in the ongoing Phase 3 study of B-VEC for the treatment of dystrophic

New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosis Company expands rare genetic lung disease pipeline with KB408 for the treatment of alpha-1 antitrypsin deficiency PITTSBURGH , April 19, 2021 (GLOBE NEWSWIRE) -- Krystal